|
 |
 |
Mace Rothenberg, MD
Director, Phase I
Drug Development Program,
Professor of Cancer Research,
Vanderbilt-Ingram Cancer Center
Professor of Medicine,
Division of Hematology/Oncology,
Vanderbilt University Medical Center
Nashville, TN |
|
|
New Frontiers in Therapy for Difficult-to-Treat Cancers —Mace Rothenberg, MD, Executive Editor
- for reference only, not for CME credit
|
| Part 1: |
New Agents and New Insights into Effective Treatment of GIST —Mace Rothenberg, MD & Emily Chan, MD, PhD |
Download PDF |
|
| Part 2: |
New Agents and New Insights into Effective Treatment of mRCC —Robert Motzer, MD |
Download PDF |
 |
New Options for Treatment of Colorectal Cancer
- for reference only, not for CME credit
|
|
Part 1:
|
Adjuvant Therapy —
No Longer One Size Fits All
|
Download PDF
|
|
|
Part 2:
|
Management and Prevention of Toxicities of Capecitabine- and Oxaliplatin-based Chemotherapies |
Download PDF
|
|
|
Part 3:
|
Optimizing Outcomes with Combination Therapy
|
Download PDF
|
 |
Treatment of Colorectal Cancer - Mace Rothenberg, MD, Executive Editor
- for reference only, not for CME credit
|
|
Part 1:
|
Dosing Considerations for Chemotherapeutic Agents in the Treatment of Colorectal Cancer —Peter Enzinger, MD |
Download PDF
|
|
|
Part 2:
|
Integration of Molecularly Targeted Agents into Chemotherapy —Mace Rothenberg, MD |
Download PDF
|
|
|
Part 3:
|
Treatment, Management, and Prevention of Toxicities Associated with Chemotherapy —Howard Hochster, MD |
Download PDF
|
 |
Advances in Treatment of Colorectal Cancer: —Mace Rothenberg, MD, Executive Editor
—for reference only, not for CME credit
|
|
Recent Data on Anti-EGFR Agents —Mace Rothenberg, MD, & Emily Chan, MD, PhD |
Download PDF |
|
 |
|
| |
|
|